EMA adopts new policies on conflicts of interest, access to documents
This article was originally published in SRA
The European Medicines Agency will publish shortly two long-awaited new policies on how the agency should manage conflicts of interest of its scientific committee experts and how it should allow better public access to EMA documents1.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.